Acumen Pharmaceuticals (ABOS) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Protara Therapeutics (TARA) over the past year, gaining 11.7% versus a loss of 46.3%. Over five years, TARA leads with a -62.1% price change compared with -84.5% for ABOS. Protara Therapeutics is the larger company by market cap ($156.6 million vs $151.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | TARA |
|---|---|---|
| Share price | $2.10 | $2.65 |
| Market cap | $151.87M | $156.60M |
| 1-day change | 0.00% | +2.32% |
| YTD return | -0.47% | -51.41% |
| 1-year return | +11.70% | -46.27% |
| 5-year return | -84.50% | -62.13% |
| EPS (TTM) | $-1.64 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $7.82 |
| 52-week low | $1.50 | $2.51 |
| Distance from 52-week high | -41.67% | -66.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +261.90% | +870.19% |
| Average volume | 435.44K | 804.10K |
| Shares outstanding | 72.32M | 59.10M |
| Employees | 60 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed TARA by 58.0 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
ABOS vs TARA FAQ
Which is bigger, Acumen Pharmaceuticals or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $156.60M compared with $151.87M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or TARA?
ABOS returned +11.70% over the past 12 months, compared with -46.27% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.